地特胰岛素联合瑞格列奈治疗老年2型糖尿病疗效及安全性的观察

摘要

目的 评价地特胰岛素(Det)联合瑞格列奈对老年T2DM患者的疗效及安全性. 方法 60例老年T2DM患者分为Det联合瑞格列奈(A)组和预混胰岛素(B)组进行治疗,观察治疗前后FBG、2hBG、HbA1c、BMI、血糖波动幅度(MAGE)、低血糖的频率及程度等情况. 结果 治疗后,两组FBG、2hBG、HbA1c下降(P＜0.05),A组低血糖发生率、程度及MAGE均低于B组(P＜0.05)；A组体重下降0.49 kg,B组体重增加1.48 kg,差异无统计学意义(P＞0.05). 结论 地特胰岛素联合瑞格列奈可降低老年T2DM患者血糖,且低血糖发生率低,安全性高.%Objective To evaluate the efficacy and safety of insulin detemir combined with repaglinide for the treatment of elderly T2DM patients.Methods All the 60 elderly T2DM inpatients were divided into the insulin detemir plus repaglinide group (group A) and premixed human insulin 30R group (group B).The observation of the changes in the levels of FBG,2 hBG,HbA1c,BMI,glucose excursion,and the incidence and severe hypoglycemia events of the two groups was done for evaluation.Results After the treatment for 12 weeks,the levels of FBG,2 hBG,and HbA1c were decreased significantly from baseline in both groups (P＜0.05).Compared with group B,the incidence and severity of hypoglycemia events as well as glucose excursion were all lower in group A (P＜0.05).In group A,the decrement of body weight was 0.49 kg,while it was 1.48 kg in group B,and the difference in body weight decrement between pre-a post-treatment was not statistically significant (P＞0.05).Conclusion For the elderly T2DM inpatients,the treatment with insulin detemir plus repaglinide improves the glucose control significantly with a lower incidence of hypoglycemia events and has a good safety.